The data are available on ClinicalTrials.gov, ID NCT00895180: Ramucirumab or Anti-PDGFR Alpha Monoclonal Antibody IMC-3G3 in Treating Patients with Recurrent Glioblastoma Multiforme. Here, PDGFRA is linked to glioblastoma.